Google DeepMind’s spinoff, Isomorphic Labs, is on the brink of initiating human trials for its AI-designed drugs, a significant development in the biotech field. Max Jaderberg, the president of Isomorphic Labs, expressed enthusiasm about these upcoming trials during a presentation at WIRED Health in London, stating, “We’re gearing up to go into the clinic,” which marks a pivotal moment for the company as it begins to evaluate the efficacy of its AI-created compounds.
The timeline for these trials has shifted, later than previously anticipated. Last year, CEO Demis Hassabis mentioned that they expected to begin human studies by the end of 2025. Founded in 2021, Isomorphic Labs utilizes the capabilities of DeepMind’s AlphaFold—an innovative AI platform that has transformed the understanding of protein structures—for the purpose of drug discovery.
Proteins, constructed from 20 different amino acids, are vital to all living organisms. Historically, researchers have struggled to predict protein structures, a problem that AlphaFold resolved with remarkable success in 2020, significantly streamlining drug development.
As of 2024, AlphaFold 3, another evolution of the platform, came into play, expanding the capabilities to model crucial molecular structures like DNA and RNA. This leap in technology is essential in drug discovery, as it provides insights into how small molecules interact with drugs.
Isomorphic Labs has formed partnerships with major pharmaceutical companies like Eli Lilly and Novartis to enhance AI drug development. Their pipeline includes exciting prospects in oncology and immunology. Jaderberg highlighted the advantages of their AI-designed molecules, describing them as engineered for potency, which allows for lower doses with potentially fewer side effects.
To prepare for clinical trials, Isomorphic Labs raised $600 million in its initial funding round and has been building a clinical development team to pursue its bold mission of “solving all disease.” Jaderberg is committed to this vision, underscoring his belief in its feasibility.
